Turkish Journal of Chemistry
Volume 46

Number 3

Article 13

1-1-2022

Ultrafiltration-based sample preparation and HPLC-UV
determination of diclofenac in human plasma samples
MERVE NENNİ
AYŞEGÜL DOĞAN
MUSTAFA ÇELEBİER
MURAT SOYSEVEN
MUSTAFA SİNAN KAYNAK

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/chem
Part of the Chemistry Commons

Recommended Citation
NENNİ, MERVE; DOĞAN, AYŞEGÜL; ÇELEBİER, MUSTAFA; SOYSEVEN, MURAT; KAYNAK, MUSTAFA
SİNAN; ABOUL-ENEIN, HASSAN Y.; and ARLİ, GÖKSEL (2022) "Ultrafiltration-based sample preparation
and HPLC-UV determination of diclofenac in human plasma samples," Turkish Journal of Chemistry: Vol.
46: No. 3, Article 13. https://doi.org/10.55730/1300-0527.3367
Available at: https://journals.tubitak.gov.tr/chem/vol46/iss3/13

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Chemistry by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Ultrafiltration-based sample preparation and HPLC-UV determination of
diclofenac in human plasma samples
Authors
MERVE NENNİ, AYŞEGÜL DOĞAN, MUSTAFA ÇELEBİER, MURAT SOYSEVEN, MUSTAFA SİNAN KAYNAK,
HASSAN Y. ABOUL-ENEIN, and GÖKSEL ARLİ

This article is available in Turkish Journal of Chemistry: https://journals.tubitak.gov.tr/chem/vol46/iss3/13

Turkish Journal of Chemistry

Turk J Chem
(2022) 46: 777-785
© TÜBİTAK
10.55730/1300-0527.3367

http://journals.tubitak.gov.tr/chem/

Research Article

Ultrafiltration-based sample preparation and HPLC-UV determination of diclofenac in
human plasma samples
1,2,

2

2

3

Merve NENNİ *, Ayşegül DOĞAN , Mustafa ÇELEBİER , Murat SOYSEVEN ,
4
5
3,6
Mustafa Sinan KAYNAK , Hassan Y. ABOUL-ENEIN , Göksel ARLİ 
1
Department of Analytical Chemistry, Faculty of Pharmacy, Çukurova University, Adana, Turkey
2
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
3
Department of Medical Services and Techniques, Yunus Emre Vocational School of Health Services, Eskişehir, Turkey
4
Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
5
Department of Pharmaceutical and Medicinal Chemistry, National Research Center, Cairo, Egypt
6
Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
Received: 04.11.2021

Accepted/Published Online: 18.01.2022

Final Version: 16.06.2022

Abstract: The sample preparation step is the initial step in pharmaceutical analysis. While ultrafiltration is a well-known technique
used in the food and pharmaceutical industries, it has rarely been used to measure the plasma concentration of active pharmaceutical
ingredients. This study aimed to analyze diclofenac sodium (DS) in human plasma samples using ultrafiltration-based sample
preparation before high-performance liquid chromatography (HPLC) analysis. The advantages and limitations of ultrafiltration-based
sample preparation in bioanalysis were evaluated by comparing the results with conventional methods. The precipitating agent was
used before ultrafiltration. The analysis was carried on an HPLC-UV system with a C18 column (250 ×4.6 mm, 5 µm) and acetonitrile :
phosphate buffer (pH 3.0, 10 mM) (70 : 30 v/v) was used as the mobile phase. The bioanalytical method was validated according to FDA
guidelines and applied to spiked samples of DS in commercial human plasma samples. The LOD and LOQ values were 0.006 µg mL–1
and 0.020 µg mL–1, respectively. The method was linear in the range of 0.025–0.50 µgmL–1 with excellent determination coefficients (R2 >
0.9991). The findings of this analysis with low LOD and LOQ values and high recovery values with high trueness and precision proved
the matrix minimizing the effect of the presented sample preparation technique.
Key words: Centrifugal filters, diclofenac, high-performance liquid chromatography, HPLC, plasma, ultrafiltration

1. Introduction
Ultrafiltration is the extraction of macromolecules from micromolecules through membranes. The diameter in the
membranes used in ultrafilters can start at 1 nm and go up to 100 nm. Proteins in macromolecule structures can easily
be separated selectively by the ultrafiltration method. Many factors affect this method’s capacity, like solute diameter,
instrumental configurations, and membrane pore diameter. Membranes are the critical component of ultrafiltration. They
consist of organic polymers. Polyamide, polysulfones, and cellulose are often used as polymers. The solution’s passage
through the ultrafilter membrane is related to the implemented pressure. The solution’s transfer through the ultrafilter
membrane is connected to the implemented pressure. Depending on their size, membranes take part as a selective
barrier that controls the transfer of molecules through them. The companies first produced filters with a criterion about
molecular size. This criterion is the “molecular weight cutoff.” It explains that molecules of specific sizes are approved to
pass through the filters. Afterward, solute-solvent and solute-membrane interactions began to be observed. Membrane
modifications have started with the development of extraction technologies. The developments also accomplish the
problems of membrane fouling and also increase the separations’ selectivity. Parameters such as pH of a solution, ionic
strength, flow rate, and percolation flow, which play a role in transport quality, still need improvement [1]. Suspended
solids and solutes with high molecular weight are filtered under pressure while passing through the membrane. In the
research and development laboratory, the ultrafiltration method has been applied for years as extraction progress in the
purification and concentration of high molecular weight solutions (especially proteins). This unique technique has found
itself in production processes, particularly in the food industry and the pharmaceutical industry [2].
* Correspondence: merve.ecz@gmail.com
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High-performance liquid chromatography (HPLC) is still one of the most dominant. When the 2000s were just
beginning, a brand new HPLC system with leading technology was designed. It is called ultra-high-performance liquid
chromatography (UPLC) [3,4]. As a result of preventing the interference of emerging matrix ingredients and maintaining
the durability of the new generation columns for the HPLC, some sample preparation procedures should be applied for
human plasma samples before the analysis. The most common sample preparation techniques for bioanalysis are the
precipitation of proteins (deprotonation) with some organic solvents [5], liquid-liquid extraction [6], and solid-phase
extraction [7]. Ultrafiltration was frequently used in the ‘90s for sample preparation [8, 9]. However, there are few studies
using ultrafiltration for this purpose. These studies draw attention to the analysis of free (unbound) API concentrations in
plasma [10].
The most commonly prescribed drugs besides antibiotics are NSAIDs. They are used in the case of inflammatory
diseases, pain, and fever. DS is a member of NSAIDs and it has antiinflammatory, analgesic, and antipyretic effects. Its
availability of it as over the counter in most countries facilitate its accessibility and increases patients’ interest in it. It is
frequently preferred for rheumatic cases and joint inflammations after surgical interventions, trauma, and migraine [11].
Similar to other group members, DS binds to plasma proteins at a rate of 99.7% [12]. DS is an active pharmaceutical
ingredient having a high bonding capacity to proteins and soluble in water. Thus, the applicability and benefits of an
innovative approach using precipitation of proteins combined with ultrafiltration-based sample preparation on biopharmaceutical analysis were presented in this study when DS was used as a model molecule. This methodology can be
adapted to analyze pharmaceuticals in blood samples regardless of their physical properties.
2. Materials and methods
2.1. Chemicals
DS and Naproxen sodium (Internal Standard, IS) were supplied from Sigma-Aldrich. Collected via K2-EDTA procedure,
pooled blank human plasma was bought from EMR chromatography, Turkey. HPLC grade acetonitrile and methanol were
supplied from Merck. Furthermore, sodium phosphate dibasic was supplied from Merck. Milli-Q water was supplied from
the Barnstead Nanopure™ system of Thermo Scientific.
2.2. Apparatus
The LC system (Agilent 1220 Infinity II) is equipped with an Ultraviolet/Visible (UV/Vis) detector, and ChemStation
software is used. Hettich UNIVERSAL 320 R centrifuge and Ika Vortex Genius were used during the analysis. Microcon®
centrifugal filters (<3 kD) were purchased from EMD Millipore.
2.3. Preparing mobile phase buffer of HPLC analysis
1.56 g of sodium dihydrogen phosphate (NaH2PO4) was dissolved in 1L water to produce 10.0 mM phosphate buffer. The
pH of the buffer was maintained to 3.0 using o-phosphoric acid.
2.4. Chromatographic conditions
Phenomenex C18 (250 × 4.6 mm, 5 µm) LC Column was utilized for separations. Mobile phase was consist of acetonitrilephosphate buffer (pH 3.0, 10 mM) (70 : 30 v/v). The flow rate was 1.0 mL min–1 in an isocratic elution mode. The injection
volume was 20 μL, and the 284 nm wavelength was employed for UV detection.
2.5. Ultrafiltration procedure
The procedure used in sample preparation: 1) Take 200 µL of plasma samples into an eppendorf tube 2) Add 200 µL of
methanol to precipitate the proteins. 3) Vortex for 1 min. 4) Take supernatant into Amicon Ultra-0.5 Centrifugal Filter
having 3kDa pores 5) Centrifuge at 14,000 rpm for 10 min. 5) Take 250 µL of the supernatants to an Eppendorf tube. 6)
Add 250 µL of mobile phase 7) Vortex for 1 min. 8) Transfer 20 µL of supernatant into HPLC (Figure 1). The final dilution
factor was 4x at the end of the ultrafiltration-based sample preparation.
2.6. Standard stock solutions
The standard stock solution of DS (1000 µg mL–1) and IS (1000 µg mL–1) were prepared in methanol. The standard stock
solution is stored at 4 °C until the analysis and freshly prepared twice a week. Stock solutions were prepared by diluting
the mobile phase to the concentrations to be used, and the ultrafiltration procedure was applied before the HPLC-UV
analysis and kept at 4 °C during the analysis and freshly prepared twice a week. Stock solutions were diluted to desired
concentrations using the mobile phase, and the ultrafiltration procedure was applied before HPLC-UV analysis.
2.7. Preparation of calibration curves
Calibration curves were constructed using the commercially available blank plasma samples. DS and IS stock solutions
were spiked in required amounts into the Eppendorf tubes containing filtrated blank plasma samples (250 µL), and the
final volume was filled up to 500 µL by adding the mobile phase to obtain final concentrations as follow: 0.025, 0.05, 0.075,
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Figure 1. Schematic presentation of the ultrafiltration procedure.

0.113, 0.15, 0.25, 0.50 µg mL–1 DS, and 0.15 µg mL–1 IS. Peak area ratios of DS/IS were plotted against concentrations of DS.
2.8. Analysis of DS spiked plasma samples
The ultrafiltration procedure was applied to the spiked plasma samples containing 0.20, 0.45, and 1.00 µg mL–1 DS and 0.60
µg mL–1 IS. When the dilution factor (4x) was considered after ultrafiltration-based sample preparation, the final solutions
consisting of 0.05, 0.1125, and 0.25 µg mL-1 of DS and 0.15 µg mL-1 of IS were analyzed by calibration equation, and the
results were calculated statistically for six replicates.
2.9. Analytical method validation
The developed method has been validated according to FDA guidelines. In addition, the calibration curves, sensitivity,
precision, trueness, and selectivity of the method were examined [13].
3. Results and discussion
3.1. Optimization of the chromatographic conditions
During the optimization process, acetate and phosphate buffers, mobile phases at various ratios, different pH and
concentration values of phosphate buffer were tried and the best chromatographic separation with the least retention
time in acceptable range was investigated. For this, methanol : water mixture was used firstly, but tailing in the peaks
observed. Afterward, acetonitrile : water mixture was used as the mobile phase, and it was observed that the tailing of the
peaks decreased and the analysis time was relatively shortened. Then, the analyzes were performed using buffer instead of
water in the mobile phase. Thus, sharper peaks were observed using buffer and it was determined that the method was not
affected by small pH changes. Finally, DS determination from plasma spiked samples was applied with a C18 (250 × 4.6
mm, 5 µm) column using a mobile phase of acetonitrile: phosphate buffer (pH 3.0, 10 mM) (70 : 30 v/v). The total analysis
time was shorter than 7 minutes under the optimum conditions.
3.2. System suitability
The system suitability parameters of the developed HPLC method according to FDA bioanalytical method validation were
injection precision (<1%), capacity factor (1 < k’ < 10), tailing factor (<1.5), theoretical plate number (>2000). Injection
precision relative standard deviation (RSD) value was found as 0.12% in 6 replicate trials. The capacity factor of 6.56,
tailing factor of 1.09, and theoretical plate number (Efficiency, N) of 5284 were calculated, indicating that the system
suitability of the developed method covers the requirements.
3.3. Method validation
3.3.1. Linearity, range, LOQ, and LOD
The calibration curve was constructed by plotting peak area ratios to the concentration of DS in the range of 0.025–0.50
µg mL–1. These concentrations represent 0.1–2.0 µg mL–1 of DS for real human plasma samples since the dilution factor
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was 4x for the ultrafiltration procedure. The regression equation and correlation coefficient calculated were y = 17.1837x
+ 0.3489 and R2 = 0.9991 (y = ax+b; y is the peak area ratio of DS to IS and x is the final concentration of DS after 4x
dilution). The chromatograms of blank plasma samples and calibration curves are given in Figure 2. The limit of detection
(LOD) and limit of quantification (LOQ) values for DS were calculated according to the signal/noise ratio equal to 3 and
10, respectively. The detected peaks which refer to 0.006 µg mL–1 and 0.020 µg mL–1 of the final DS concentrations were
found as LOD and LOQ, respectively for the proposed methodology (Table 1).
3.3.2. Trueness and precision of the developed method
Three different concentrations of DS (0.0500, 0.1125, and 0.2500 µg mL–1) within the linear range as low medium and high
concentrations were analyzed in three consecutive days (interday studies) and three times within the same day (intra-day
studies). The biases of intra-day and interday studies were between –4.77 and 3.23 which proves the high trueness of the
method.
The relative standard deviations of intra-day and interday studies were between 2.86% –5.99% respectively, which were
below the FDA’s limits of 15% for bioanalytical analysis. These results indicate that the developed method was accurate
and precise. Intermediate precision was also controlled by injection repeatability, and a value of 0.12%, which is below the
acceptance criteria of 2%, shows the high precision of the method (Table 2).
3.3.3. Selectivity of the developed method
The selectivity criteria for DS were examined from chromatograms in the presence of plasma. Therefore, chromatograms
of blank plasma, DS, and IS spiked into plasma and water were compared (Figure 3). The interference peaks coming from
matrix components were tracked to show if they interfere with the peaks of DS and IS. As was expected, the water-soluble
matrix components eluted with the dead volume where DS and IS were eluted at 3.20 and 2.21 min.
3.4. Analysis of spiked plasma samples
DS spiked plasma samples (0.20, 0.45, and 1.00 µg mL–1 DS and 0.60 µg mL–1 IS) were prepared as defined in the experimental
part. The dilution factor after ultrafiltration-based extraction was 4x, which means the final solutions of the spiked samples
contain 0.05, 0.1125, and 0.25 µg mL–1 of DS, and 0.15 µg mL–1 of IS. These solutions were analyzed using the developed
HPLC method, and the results were calculated using the regression equation (Table 1) get from calibration standards. The
analysis results showed that the recovery for DS spiked into plasma samples was between 93.11% and 104.92% for three
different concentration range.

Figure 2. The overlaid chromatograms of blank plasma sample and calibration curve samples (0.025–0.5 µg mL–1 of DS and 15 µg mL–1
of IS) under experimental conditions: Mobile phase: acetonitrile : phosphate buffer (pH 3.0, 20 mM) (70 : 30 v/v), flow rate: 1 mL min–1,
injection volume: 20 μL, detection wavelength: 284 nm, IS concentration for calibration curve: 0.15 µg mL–1.
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Table 1. Linearity of the developed method (n = 6).
Regression equation for the final concentration (4x diluted) *

y = 17.3936x + 0.3390

Standard error of intercept

0.0143

Standard error of slope

0.2027

Regression coefficient (R )

0.9991

2

Range for the final concentration (4x diluted) (µg mL–1)

0.025–0.5

The range for the targeted concentration (µg mL )

0.1–2.0

Number of data points

7

–1

LOQ for the final concentration (µg mL )

0.020

LOD for the final concentration (µg mL–1)

0.006

–1

* Based on six calibration curves where y: peak area ratio of DS to IS and x: final concentration of
DS as µg mL–1.

Table 2. Analysis of spiked plasma samples (n = 6).
–1
Added DS into the blank 0.0500 µg mL
plasma samples
intraday

0.1125 µg mL–1
interday

intraday

0.2500 µg mL–1
interday

intraday

interday

Found DS in the blank
plasma samplesa

0.0476 ± 0.0024 0.0495 ± 0.0021 0.1161 ± 0.0063 0.1136 ± 0.0068 0.2467 ± 0.0093 0.2383 ± 0.0068
µg mL–1
µg mL–1
µg mL–1
µg mL–1
µg mL–1
µg mL–1

Bias of the analysisb

–4.77

–0.94

3.23

0.93

–1.31

–4.70

Relative standard
4.96%
deviation of the results %

4.19%

5.40%

5.99%

3.79%

2.86%

Recovery %

95.21%

100.21%

102.48%

94.37%

99.26%

98.99%

Found: mean ± standard error (n = 6), bBias: [(Found-Added)/Added] × 100

a

As seen from the results, the proposed ultrafiltration-based extraction coupled with the developed RP-HPLC method
could be used successfully to analyze of DS in human plasma samples.
3.5. An overview of the discussion
The ultrafiltration method is used in industry as a separation process in the purification and concentration of macromolecular
and protein solutions. The use of ultrafiltration in the industry is quite common (such as in the dairy industry, the food
industry, and the pharmaceutical industry [2]). Membranes made of organic polymers are used in ultrafilters. Polyamide,
polysulfones, and cellulose are often used as polymers. Ultrafiltration systems are classified according to the membrane’s
structure, morphology, and size [1]. The attention of ultrafiltration in a sample preparation method was demonstrated at
the beginning of 2005. It has been used frequently in the Human Metabolome Project [14]. This project has been used in
nontargeted metabolomics approaches (for targeted and especially untargeted metabolomics, where the method usually
does not need to be selective to some specific metabolite) [15]. Also, some applications of UF in metabolome analysis of
biological materials are summarized by Vuckovic [16].
In a general article review, it is obvious which there have been confined data over the past decade using ultrafiltration
like a sample preparation method for pharmaceutical analysis. These articles focus specifically on analyzing of unbound
(free) API concentrations in plasma samples. Lately, Kratzer et al. [17] published work on detecting unbound plasma
concentrations of tazobactam and ceftolozane. This article analyzed with HPLC-UV using the ultrafiltration sample
preparation technique. Moreover, the procedure applied in this study was similar to that applied in previous studies [18].
There is no DS analysis from plasma by ultrafiltration method in the literature. However, various pharmaceuticals such
as carbamazepine, diclofenac, naproxen are retained by nanofiltration membranes in wastewater treatment plants [19].
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Figure 3. The overlaid chromatograms of blank plasma sample, DS spiked into the water and spiked into plasma samples under
experimental conditions. DS concentration is 0.45 µg mL–1, and IS concentration is 10 µg mL–1 before the extraction procedure.

In pharmaceutical analyses, HPLC is a widely used chromatographic separation technique [20–27]. However, the
most critical step in the pharmaceutical analysis is the purification of the sample to prevent interference in the analysis.
Researchers are still developing automated and easy-to-follow procedures to save time and chemicals used. Most researchers
prefer common sample preparation procedures such as precipitation of proteins via organic solvents, liquid-liquid, and
solid-phase extraction. At the same time, the ultrafiltration technique offers researchers a one-step and easily applicable
sample preparation technique from biological materials [28].
Ultrafiltration-based sample preparation for the determination of DS in human plasma samples before HPLC-UV
analysis was successfully applied in the present study. Since the ultrafiltration method acts as a sieve that filters the
proteins, it is an effective method that can be used to measure the free concentration of APIs in plasma samples [17, 29].
The drug molecules bound to albumin in the blood remain unfiltered, and the unbound drug molecules that transfer to
the membrane can be analyzed. Commercial and selectively existing sample preparation procedures such as QUECHERS,
solid-phase extraction, and liquid-phase extraction have dominated the pharmaceutical analysis through technological
improvements and utilized sample preparation techniques for the last twenty years [30, 31]. There have been limited
reports to analyze the total concentration of APIs through ultrafiltration-based sample preparation [32].
Pharmacokinetics is a subbranch of pharmacology that examines the processes of absorption, distribution,
transformation, and disposal of drugs into the body by establishing mathematical models. In pharmacokinetic studies,
bio-pharmaceutical analysis is critical in examining the behavior of APIs in biological systems. Therefore, researchers aim
to analyze the concentration of drugs in various conditions at different time rates. Protein binding can affect drug activity
in one of two ways; the first changes the effective concentration of the drug, the latter changes the rate of elimination
of the drug. Drugs are mainly bound to plasma proteins such as albumin, alpha-1-acid glycoprotein, lipoproteins [33].
Drugs bind to plasma proteins depending on their specific drug’s affinity. DS is a member of NSAIDs, and it binds to
plasma proteins (mainlyalbumin) at a rate of 99.7%, as mentioned above [12]. An alternative and more straightforward
approach, protein precipitation, is used to release protein-bound drugs. Methanol denatures proteins by acting on the
bonds that hold parts of the protein folding. Various separation techniques of unbound drug fractions are known, such as
ultrafiltration, ultracentrifugation, and equilibrium dialysis. Since the primary shortcoming of ultrafiltration is the analysis
of free drug concentration on direct filtration of plasma samples, we used a protein precipitation agent, methanol, before
the filtration procedure. In general, protein precipitation is required to release drugs fully, but shows that filtration is critical
to minimize matrix effects. Using 1 : 1 (v/v) human plasma-methanol allowed us to reach acceptable recovery values for DS
in our experimental conditions. Thus, it might be discussed if the researchers could employ ultrafiltration, a nonselective
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sample preparation technique, in pharmacokinetic studies. Precipitation of proteins combined with ultrafiltration
could allow researchers an easy to apply one-step sample preparation without any variation factor depending on the
analyst’s experience. In addition, ultrafiltration-based sample preparation could allow researchers to prepare 96 samples
simultaneously while using a suitable centrifuge for this purpose. Compared with solid-phase extraction, it can leave the
analyst independent and save time since it does not require any buffer preparation or washing steps. In our experiments, we
injected more than a hundred samples, and the column backpressure was stable during these analyzes. When we compared
the chromatograms for protein-free supernatant after ultrafiltration and before ultrafiltration, we did not recognize any
significant differences. However, we realized that the direct injection of supernatant without ultrafiltration caused an
increased back pressure in HPLC analysis after a few dozens of injections. Our previous experiences also support this
critical effect on column lifetime. On the other hand, using an individual ultrafiltration device for every single sample
may cause a dramatic effect on total analysis costs. In this point, it should be mentioned that the ultrafiltration-based
sample preparation process presented in this study does not need any optimization procedure and researchers should
consider the HPLC separation of the API from baseline after ultrafiltrated. The developed method and the ultrafiltration
sample preparation step were compared with the previous methods published on diclofenac analysis from plasma using
conventional sample preparation steps. Type of extraction, sample preparation solvents used, LOD, LOQ, and recovery
values are presented and compared in Table 3 [34–39].
According to Table 3, the lowest LOD value belongs to the developed method. While the LOQ value of this method
is the same in only one of the compared methods, it is higher in other methods. In other words, the sensitivity of the
developed method, which is one of the validation parameters, is higher. In addition, an LC-Tandem MS device was used
in one of the comparison methods. Although the sensitivity of this device is generally known to be higher than HPLC, the
developed method was found to be more sensitive. However, the recovery value, which is another validation parameter of
the developed method, is higher than other methods (especially the solid phase extraction method).
When the developed method is compared in terms of time and cost, it may seem disadvantageous at first glance, but
when it is examined in general, it is not. When the methods are compared, one ultrafilter, one solid phase extraction
cartridge, and various solvents are used for each sample. The cost per sample appears to be lower in liquid-liquid extraction.
However, during these analyses, the column backpressure was stable even though we ultimately injected more than a
hundred samples in ultrafiltration. This means that the ultrafiltration method increases the column life and automatically
reduces the cost. While the extraction steps are repeated to increase the efficiency of liquid-liquid and solid-phase
extraction, there is no repetition in the ultrafiltration method.
In short, the advantage of the developed method is high recovery and sensitivity while low cost and time-consuming.

Table 3. Comparison of DS analysis from plasma with different extraction techniques.
Extraction
type

Mobile phase

Developed HPLC

Ultrafiltration

Acetonitrile : phosphate buffer (pH 3.0, 10 mM)
0.006/0.020
(70 : 30 v/v)

98.27%

Reported HPLC [34]

Solid Phase
Extraction

MeOH : Water
(pH 3.3) (63 : 37 v/v)

89.8%

Reported HPLC [35]

Solid Phase
Extraction

Acetonitrile : phosphate buffer containing 0.1%
– /0.075
trifluoroacetic acid (pH 7.0, 20 mM) (35 : 65 v/v)

93.8–101.2%

Reported
LC-Tandem MS [36]

Solid Phase
Extraction

Acetonitrile : water containing 0.2% acetic acid
(80 : 20 v/v)

– /0.025

79%

Reported HPLC [37]

Liquid-Liquid Acetonitrile : water
Extraction
(pH 3.3) (50 : 50 v/v)

0.015/0.025

110%

Reported HPLC [38]

Liquid-Liquid Acetonitrile : water
Extraction
(pH 4) (55 : 45 v/v)

0.01/0.02

-

Reported HPLC [39]

Liquid-Liquid Acetonitrile : water
Extraction
(pH 3.3) (50 : 50 v/v)

0.00895/0.02712 98.75–99.32%

Analyte Method

DS

LOD/LOQ
(µg mL-1)

0.042/1.000

Recovery
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4. Conclusion
The sample preparation step is the essential point for pharmaceutical analysis to clean up the sample and avoid
interferences’ peaks. Although ultrafiltration is not a novel sample preparation technique to overcome all the negative
impacts of a complex biological matrix, it has mainly found itself a place in proteomics and metabolomics studies. The
proposed methodology using ultrafiltration in this study can be an example of the feasibility of this unique technique
on biopharmaceutical analysis. It can be adopted to pharmacokinetic studies requiring the analysis of lots of samples.
The acceptable recovery results of DS, which is very eager to bind the proteins, can lead chromatographers to employ
the workflow presented in this study on further studies. In addition, it increases the column life by reducing the counter
pressure in HPLC in sample injection prepared by ultrafiltration. It will provide convenience for researchers by preventing
colon changes during analysis.
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